title: Indomethacin tocolysis and neurodevelopmental outcome.
abstract: OBJECTIVE
  To compare the neurodevelopmental outcomes, at 30-42 months adjusted age, between infants exposed to antenatal indomethacin and those unexposed to antenatal indomethacin.
  
  
  METHODS
  This was a retrospective cohort study. The study cohort consisted of all nonanomalous infants with birth weight ≤ 1250 g and/or gestational age ≤ 28 wks born between 2000 and 2003, who completed neurodevelopmental assessments between 30-42 months adjusted age. The authors compared the neurodevelopmental outcomes of infants exposed and unexposed to antenatal indomethacin.
  
  
  RESULTS
  Of the 321 infants, 75 infants (23%) exposed to antenatal indomethacin were lower in gestational age (26.4 vs 27.8 wks). In univariate analysis, infants exposed to antenatal indomethacin had significantly increased incidence of patent ductus arteriosus (PDA) (60% vs. 39%), surgical PDA ligation (40% vs. 18%) and bronchopulmonary dysplasia (81% vs. 60%). There was no significant difference in cerebral palsy, cognitive delay, deafness, blindness and major disability between the two groups. In multivariable logistic regression analysis, antenatal indomethacin exposure was not associated with cerebral palsy (OR, 0.70; 95% CI, 0.22-2.18), cognitive delay (OR, 0.56; 95% CI, 0.28-1.12) or neurodevelopmental disability (OR, 0.50; 95% CI, 0.21-1.19).
  
  
  CONCLUSIONS
  Neurodevelopmental outcome of preterm infants exposed to antenatal indomethacin is equivalent to those unexposed to antenatal indomethacin, despite being born earlier.
authors.affiliation: Division of Neonatology, Department of Pediatrics, Institute for Child and Maternal Health, University of Calgary, Calgary, Alberta, Canada. asoraish@ucalgary.ca
authors.forename: Amuchou S
authors.initials: AS
authors.lastname: Soraisham
authors.forename: Reg
authors.initials: R
authors.lastname: Sauve
authors.forename: Nalini
authors.initials: N
authors.lastname: Singhal
mesh_terms: D000328:Adult; D002675:Child, Preschool; D015331:Cohort Studies; D002658:Developmental Disabilities / Q000175:diagnosis*; D005260:Female; D006801:Humans; D007213:Indomethacin / Q000009:adverse effects*; D008297:Male; D008431:Maternal-Fetal Exchange; D009422:Nervous System Diseases / Q000139:chemically induced*; D011247:Pregnancy; D012189:Retrospective Studies; D015145:Tocolysis / Q000009:adverse effects*; D015149:Tocolytic Agents / Q000009:adverse effects*
chemical_list: D015149:Tocolytic Agents; D007213:Indomethacin